Search

Your search keyword '"Attolico, Imma"' showing total 21 results
Start Over Author "Attolico, Imma" Language english
21 results on '"Attolico, Imma"'

1. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors

Author

Mulas, Olga, Caocci, Giovanni, Stagno, Fabio, Bonifacio, Massimiliano, Annunziata, Mario, Luciano, Luigiana, Orlandi, Ester Maria, Abruzzese, Elisabetta, Sgherza, Nicola, Martino, Bruno, Albano, Francesco, Galimberti, Sara, Pregno, Patrizia, Bocchia, Monica, Castagnetti, Fausto, Tiribelli, Mario, Binotto, Gianni, Gozzini, Antonella, Capodanno, Isabella, Fozza, Claudio, Luzi, Debora, Efficace, Fabio, Simula, Maria Pina, Scaffidi, Luigi, De Gregorio, Fiorenza, Elena, Chiara, Trawinska, Malgorzata Monika, Cattaneo, Daniele, Attolico, Imma, Baratè, Claudia, Pirillo, Francesca, Sicuranza, Anna, Gugliotta, Gabriele, Stella, Rossella, Scalzulli, Emilia, Iurlo, Alessandra, Foà, Robin, Breccia, Massimo, and La Nasa, Giorgio

Published
2020
Full Text
View/download PDF

2. Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Author

Stagno, Fabio, Abruzzese, Elisabetta, Iurlo, Alessandra, Pane, Fabrizio, Attolico, Imma, Sportoletti, Paolo, Pregno, Patrizia, Galimberti, Sara, Scappini, Barbara, Miglino, Maurizio, Siragusa, Sergio, Capodanno, Isabella, Valsecchi, Diletta, Nardozza, Aurelio Pio, Coco, Paola, Rosti, Gianantonio, Saglio, Giuseppe, and Breccia, Massimo

Published
2022
Full Text
View/download PDF

3. Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Author

Bucelli, Cristina, Capodanno, Isabella, Miggiano, Maria Cristina, Cavazzini, Francesco, Leonetti Crescenzi, Sabrina, Russo, Sabina, Carmosino, Ida, Annunziata, Mario, SORA, Federica, Bonifacio, Massimiliano, Luciano, Luigiana, Caocci, Giovanni, Loglisci, Giuseppina, Elena, Chiara, Lunghi, Francesca, Mullai, Rikard, Attolico, Imma, Binotto, Gianni, Crisa', Elena, Sportoletti, Paolo, Di Veroli, Ambra, Scortechini, Anna Rita, Leporace, Anna Paola, Maggi, Alessandro, Crugnola, Monica, Stagno, Fabio, Sancetta, Rosaria, Murgano, Pamela, Rapezzi, Davide, Luzi, Debora, Vincelli, Jolanda Donatella, Galimberti, Sara, Bocchia, Monica, Fava, Carmen, Malato, Alessandra, Abruzzese, Elisabetta, Saglio, Giuseppe, Specchia, Giorgina, Breccia, Massimo, Iurlo, Alessandra, Tiribelli, Mario, and Latagliata, Roberto

Published
2023
Full Text
View/download PDF

5. Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients

Author

Attolico, Imma, Tarantini, Francesco, Carluccio, Paola, Schifone, Claudia, Delia, Mario, Gagliardi, Vito Pier, Perrone, Tommasina, Gaudio, Francesco, Longo, Chiara, Giordano, Annamaria, Sgherza, Nicola, Curci, Paola, Rizzi, Rita, Ricco, Alessandra, Russo Rossi, Antonella Vita, Albano, Francesco, Larocca, Angela Maria Vittoria, Vimercati, Luigi, Tafuri, Silvio, and Musto, Pellegrino

Published
2021
Full Text
View/download PDF

6. Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Author

Latagliata, Roberto, Capodanno, Isabella, Miggiano, Maria Cristina, Bucelli, Cristina, Cavazzini, Francesco, Leonetti Crescenzi, Sabrina, Russo, Sabina, Colafigli, Gioia, Annunziata, Mario, Sora, Federica, Bonifacio, Massimiliano, Luciano, Luigiana, Caocci, Giovanni, Loglisci, Giuseppina, Elena, Chiara, Mullai, Rikard, Attolico, Imma, Binotto, Gianni, Crisà, Elena, Iurlo, Alessandra, Sportoletti, Paolo, Di Veroli, Ambra, Scortechini, Anna Rita, Leporace, Annapaola, Maggi, Alessandro, Crugnola, Monica, Stagno, Fabio, Sancetta, Rosaria, Murgano, Pamela, Rapezzi, Davide, Luzi, Debora, Bocchia, Monica, Fava, Carmen, Malato, Alessandra, Vincelli, Jolanda Donatella, Abruzzese, Elisabetta, Saglio, Giuseppe Nicola, Specchia, Giorgina, Breccia, Massimo, and Tiribelli, Mario

Published
2021
Full Text
View/download PDF

7. Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

Author

Breccia, Massimo, Luciano, Luigia, Annunziata, Mario, Attolico, Imma, Malato, Alessandra, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Scortechini, Anna Rita, Cascavilla, Nicola, Di Renzo, Nicola, Impera, Stefana, Lunghi, Monia, Santoro, Marco, Castagnetti, Fausto, Maggi, Alessandro, Sargentini, Valeria, Piciocchi, Alfonso, Galimberti, Claudia, and Iurlo, Alessandra

Published
2021
Full Text
View/download PDF

9. Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Author

Caocci, Giovanni, Mulas, Olga, Capodanno, Isabella, Annunziata, Mario, Abruzzese, Elisabetta, Galimberti, Sara, Tiribelli, Mario, Luciano, Luigiana, Martino, Bruno, Castagnetti, Fausto, Binotto, Gianni, Pregno, Patrizia, Stagno, Fabio, Bocchia, Monica, Albano, Francesco, Luzi, Debora, Fozza, Claudio, Bonifacio, Massimiliano, Elena, Chiara, Gozzini, Antonella, Simula, Maria Pina, Trawinska, Malgorzata Monika, Baratè, Claudia, Stella, Rossella, De Gregorio, Fiorenza, Gugliotta, Gabriele, Pirillo, Francesca, Cattaneo, Daniele, Sicuranza, Anna, Attolico, Imma, Scaffidi, Luigi, Scalzulli, Emilia, Iurlo, Alessandra, Foà, Robin, Breccia, Massimo, and La Nasa, Giorgio

Published
2020
Full Text
View/download PDF

10. Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients

Author

Attolico, Imma, Latagliata, Roberto, Breccia, Massimo, Abruzzese, Elisabetta, Iurlo, Alessandra, Capodanno, Isabella, Annunziata, Mario, Galimberti, Sara, Tiribelli, Mario, Martino, Bruno, Gozzini, Antonella, Scortechini, Anna Rita, Elena, Chiara, Castagnetti, Fausto, Luciano, Luigia, Fava, Carmen, Pregno, Patrizia, Stagno, Fabio, Bergamaschi, Micaela, Binotto, Gianni, Bonifacio, Massimiliano, Caocci, Giovanni, Crugnola, Monica, Tarantini, Francesco, Specchia, Giorgina, and Albano, Francesco

Published
2018
Full Text
View/download PDF

11. Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors

Author

Caocci, Giovanni, Mulas, Olga, Abruzzese, Elisabetta, Iurlo, Alessandra, Attolico, Imma, Galimberti, Sara, Luciano, Luigia, Sgherza, Nicola, Bonifacio, Massimiliano, Annunziata, Mario, Gozzini, Antonella, Orlandi, Ester Maria, Stagno, Fabio, Binotto, Gianni, Fozza, Claudio, Trawinska, Malgorzata Monika, Cattaneo, Daniele, Albano, Francesco, Baratè, Claudia, De Gregorio, Fiorenza, Scaffidi, Luigi, Elena, Chiara, Molica, Matteo, La Nasa, Giorgio, Foà, Robin, and Breccia, Massimo

Published
2018
Full Text
View/download PDF

12. Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside

Author

Olivieri, Jacopo, Coluzzi, Sabrina, Attolico, Imma, and Olivieri, Attilio

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

Chronic Graft Versus Host Disease (cGVHD) is a major complication of allogeneic stem-cell transplantation (SCT). In many inflammatory fibrotic diseases, such as Systemic Scleroderma (SSc) and cGVHD with fibrotic features, an abnormal activation of transforming growth factor (TGFβ) and platelet-derived growth factor receptor (PDGF-R) pathways have been observed. Tyrosin Kinase Inhibitors (TKIs), which are currently used for treatment of patients with Chronic Myeloid Leukemia (CML), share potent antifibrotic and antiinflammatory properties, being powerful dual inhibitors of both PDGF-R and TGFβ pathways. Moreover accumulating in vitro data confirm that TKIs, interacting with the TCR and other signalling molecules, carry potent immunomodulatory effects, being involved in both T-cell and B-cell response. Translation to the clinical setting revealed that treatment with Imatinib can achieve encouraging responses in patients with autoimmune diseases and steroid-refractory cGVHD, showing a favourable toxicity profile. While the exact mechanisms leading to such efficacy are still under investigation, use of TKIs in the context of clinical trials should be promoted, aiming to evaluate the biological changes induced in vivo by TKIs and to assess the long term outcome of these patients. Second-generation TKIs, with more favourable toxicity profile are under evaluation in the same setting.

Published
2011
Full Text
View/download PDF

15. Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study

Author

Offidani, Massimo, Maracci, Laura, Corvatta, Laura, Anna Marina, Liberati, Ballanti, Stelvio, Attolico, Imma, Caraffa, Patrizia, Alesiani, Francesco, Caravita di Toritto, Tommaso, Gentili, Silvia, Tosi, Patrizia, Brunori, Marino, Derudas, Daniele, Ledda, Antonio, Gozzetti, Alessandro, Cellini, Claudia, Malerba, Lara, Mele, Anna, Felici, Stefano, Galimberti, Sara, Mondello, Patrizia, Pulini, Stefano, Coppetelli, Ugo, Fraticelli, Paolo, Rizzi, Rita, and Leoni, Pietro

Published
2014
Full Text
View/download PDF

16. research paper B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia.

Author

Ruchlemer, Rosa, Parry-Jones, Nilima, Brito-Babapulle, Vasantha, Attolico, Imma, Wotherspoon, Andrew C., Matutes, Estella, and Catovsky, Daniel

Subjects
LYMPHOCYTIC leukemia, CYCLINS, BONE marrow, CYTOGENETICS, IMMUNOHISTOCHEMISTRY, IMMUNOGLOBULINS
Abstract

We reviewed eight cases that were diagnosed before 1995 with B-prolymphocytic leukaemia (B-PLL) harbouring t(11;14)(q13;q32) and/or cyclin D1 staining. Thirteen B-PLL patients without t(11;14) were selected as controls. Peripheral blood, bone marrow and histological sections were re-examined without cytogenetic information. Final diagnosis was made using morphology, cytogenetics, immunophenotype and immunohistochemistry. Clinical characteristics were similar for both groups except for younger age, male predominance and extranodal involvement in cases with t(11;14). CD5 was more frequently positive in the t(11;14)+ group (80%) than in the t(11;14)− group (31%). Surface membrane immunoglobulin was strongly expressed by all t(11;14)+ cases, but only 45% of t(11;14)− cases. Histopathological and cytological review of cases with t(11;14) showed an infiltrate with a mixture of cells, some resembling prolymphocytes and others with mantle cell lymphoma (MCL) morphology. Blood films of cases with t(11;14) showed features suggestive of B-PLL in three, and in others, a mixture of cells resembling MCL and nucleolated ones; none corresponded to the blastoid form of MCL. We suggest that ‘B-PLL’ with t(11;14) may represent a splenomegalic form of MCL evolving with leukaemia. These cases illustrate the importance of tissue diagnosis with cyclin D1 staining and fluorescence in situ hybridization analysis in B-cell leukaemia with prolymphocytic features. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

20. Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.

Author

Mulas O, Caocci G, Annunziata M, Martino B, Luciano L, Castagnetti F, Pregno P, Galimberti S, Albano F, Orlandi EM, Sgherza N, Iurlo A, Bonifacio M, Binotto G, Gozzini A, Bocchia M, Abruzzese E, Fozza C, Simula MP, De Gregorio F, Gugliotta G, Pirillo F, Baratè C, Attolico I, Elena C, Cattaneo D, Scaffidi L, Sicuranza A, Trawinska MM, Scalzulli E, Foà R, Breccia M, and La Nasa G

Subjects
Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Survival Rate, Chromosomes, Human, Pair 22 genetics, Chromosomes, Human, Pair 22 metabolism, Chromosomes, Human, Pair 9 genetics, Chromosomes, Human, Pair 9 metabolism, Fusion Proteins, bcr-abl blood, Fusion Proteins, bcr-abl genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Pyrimidines administration & dosage, RNA, Messenger blood, RNA, Messenger genetics, RNA, Neoplasm blood, RNA, Neoplasm genetics, Translocation, Genetic
Published
2020
Full Text
View/download PDF

21. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.

Author

Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M, Orlandi EM, Albano F, Galimberti S, Iurlo A, Pregno P, Sgherza N, Martino B, Binotto G, Castagnetti F, Gozzini A, Bocchia M, Fozza C, Stagno F, Simula MP, De Gregorio F, Trawinska MM, Scaffidi L, Elena C, Attolico I, Baratè C, Cattaneo D, Pirillo F, Gugliotta G, Sicuranza A, Molica M, La Nasa G, Foà R, and Breccia M

Subjects
Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Female, Humans, Italy epidemiology, Life Expectancy, Long Term Adverse Effects chemically induced, Long Term Adverse Effects mortality, Male, Mortality, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Risk Adjustment methods, Aniline Compounds administration & dosage, Aniline Compounds adverse effects, Cardiotoxicity etiology, Cardiotoxicity mortality, Cardiotoxicity prevention & control, Cardiovascular Diseases chemically induced, Cardiovascular Diseases mortality, Cardiovascular Diseases prevention & control, Dasatinib administration & dosage, Dasatinib adverse effects, Imidazoles administration & dosage, Imidazoles adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Nitriles administration & dosage, Nitriles adverse effects, Pyridazines administration & dosage, Pyridazines adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Quinolines administration & dosage, Quinolines adverse effects
Abstract

Background: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2 ndG /3 rdG TKIs) in the real-life practice., Methods: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib., Results: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control., Conclusion: Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered., (Copyright © 2019 Elsevier B.V. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results